Regencell Bioscience Holdings

Regencell Bioscience Holdings

Regencell Bioscience Holdings Ltd was incorporated in 2014 and is headquartered in Hong Kong. The company operates through its subsidiaries and focuses on research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). The firm has not publicly disclosed an AUM or deployment figure, as it operates as a corporate entity rather than an investment vehicle. The company's primary asset pipeline includes three formulated TCM candidates. Its lead product candidate, RGC-COV19FM, was originally designed to treat COVID-19 symptoms and later redirected toward post-COVID cognitive dysfunctions. Its core neurological candidates, RGC-ADHD and RGC-ASD, are under development to target mild to moderate ADHD and ASD, respectively. The firm's geographic focus centers on mainland China and Hong Kong, where its TCM licensure and clinical trial infrastructure are based. In July 2021, Regencell priced its IPO at $9.50 per share on the Nasdaq Capital Market under the ticker RGC, generating approximately $23 million in gross proceeds. The offering was self-underwritten, a rare structure for foreign issuers listing in the United States. The firm maintains a lean operational footprint with no disclosed adjacent investment vehicles, philanthropic foundations, or external GP commitments. Regencell's structural differentiator is its self-underwritten public listing combined with an operating-company posture. Unlike venture-backed biotech platforms that rely on successive private funding rounds, Regencell accessed U.S. capital markets directly to fund clinical work on TCM protocols that fall largely outside the purview of Western institutional allocators. This regulatory arbitrage on sourcing — raising public U.S. capital for onshore Chinese TCM research — remains its primary architectural distinction.